Document is current
Any future updates will be listed below
-
Authors
Maguire, William F. https://orcid.org/0000-0002-3288-8863
Schmitz, John C. https://orcid.org/0000-0001-6321-9606
Scemama, Jonas
Czambel, Ken
Lin, Yan https://orcid.org/0000-0001-9413-3960
Green, Anthony G.
Wu, Shaoyu
Lin, Huang
Puhalla, Shannon
Rhee, John
Stoller, Ronald
Tawbi, Hussein
Lee, James J.
Wright, John J.
Beumer, Jan H. https://orcid.org/0000-0002-8978-9401
Chu, Edward
Appleman, Leonard J. https://orcid.org/0000-0003-4951-7388
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01749384 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors
https://doi.org/10.1007/s00280-021-04317-y
-
Funding
Funding for this research was provided by:
National Cancer Institute (UM1-CA186690, U24CA247643, P30-CA47904, T32 CA193205, R50 CA211241)
- License Information
-
More Information
Article History
Received: 15 February 2021
Accepted: 10 June 2021
First Online: 23 June 2021
Declarations
:
: The authors declare that they have no conflict of interest.
: The study was approved by the Institutional Review Board at the University of Pittsburgh and was conducted in accordance with the Declaration of Helsinki for human subject protection. All patients provided written informed consent prior to enrollment.
